ClinicalTrials.gg
CompletedNCT03231969Updated Mar 16, 2023Results posted

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

A Phase 2 interventional study of Bilastine 0.2% and Bilastine 0.4% in Allergic Conjunctivitis, sponsored by Faes Farma, S.A.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Faes Farma, S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
33rd of 90
121 · median 94
Started
2017
with 3 others
Phase 2
25 of 95
4 open now
Registered
66th of 95
by date
Lead sponsor
3 of 95
Faes Farma, S.A.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 33rd largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2017, is one of 25 in phase 2, and was the 66th registered.

Conjunctivitis, Allergic

210 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • be at least 18 years old
  • be willing and able to avoid all disallowed medications and contact lenses
  • must have a pregnancy test if of
  • must be able to read an eye chart from 10 feet away

Key Exclusion Criteria:

  • must not have any allergies to the study medications
  • must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
  • must not have used immunotherapy in the last 2 years
  • must not have used an drug or device in the past 30 days or concurrently enrolled in another investigational trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Bilastine 0.2%

    Bilastine Ophthalmic solution 0.2% 1 drop in each eye at 3 separate times during a 25 day period.

    Drug: Bilastine 0.2%

  • Experimental
    Bilastine 0.4%

    Bilastine Ophthalmic solution 0.4% 1 drop in each eye at 3 separate times during a 25 day period.

    Drug: Bilastine 0.4%

  • Experimental
    Bilastine 0.6%

    Bilastine Ophthalmic solution 0.6% 1 drop in each eye at 3 separate times during a 25 day period.

    Drug: Bilastine 0.6%

  • Placebo comparator
    Bilastine 0%

    Vehicle of Bilastine Ophthalmic Solution 1 drop in each eye at 3 separate times during a 25 day period.

    Drug: Bilastine 0%

Interventions

  • 1 drop in each eye at 3 separate times during a 25 day period.

  • 1 drop in each eye at 3 separate times during a 25 day period.

  • 1 drop in each eye at 3 separate times during a 25 day period.

  • DrugBilastine 0%

    1 drop in each eye at 3 separate times during a 25 day period.

06

What researchers measure

Primary outcomes

  1. Ocular Itching

    The primary efficacy measure was ocular itching evaluated by the subject post-CAC (Conjunctival Allergen Challenge) at Visits 4b, 5b, and 6, using a 0 to 4 Ora Calibra scale: 0 = none (normal, no itching), 4 = incapacitating itch.

    Time frame: The outcome measure was assessed at Visit 4b (Day 1, 16h post treatment), Visit 5b (Day 15 ±3, 8h post treatment), and Visit 6 (Day 22 ±3, 15 minutes post treatment).

07

Results

Posted Nov 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneBilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%
Started30303130
Completed28283030
Not completed2210

Outcome measures

PrimaryOcular Itching

The primary efficacy measure was ocular itching evaluated by the subject post-CAC (Conjunctival Allergen Challenge) at Visits 4b, 5b, and 6, using a 0 to 4 Ora Calibra scale: 0 = none (normal, no itching), 4 = incapacitating itch.

Time frame:
The outcome measure was assessed at Visit 4b (Day 1, 16h post treatment), Visit 5b (Day 15 ±3, 8h post treatment), and Visit 6 (Day 22 ±3, 15 minutes post treatment).
Reported as:
Mean · units on a scale
Ocular Itching
units on a scaleBilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0% (Vehicle)
Visit 4b: 3 minutes Post-CAC1.908 ± 0.78091.925 ± 0.94491.177 ± 1.03322.758 ± 0.7146
Visit 4b: 5 minutes Post-CAC2.075 ± 0.78282.117 ± 0.95311.218 ± 1.12683.017 ± 0.5979
Visit 4b: 7 minutes Post-CAC2.092 ± 0.76982.100 ± 1.07601.218 ± 1.11572.917 ± 0.5884
Visit 5b: 3 minutes Post-CAC1.397 ± 1.10501.250 ± 0.88720.708 ± 0.89082.558 ± 0.8032
Visit 5b: 5 minutes Post-CAC1.466 ± 0.93001.464 ± 0.95920.817 ± 1.05032.642 ± 0.7505
Visit 5b: 7 minutes Post-CAC1.379 ± 0.85731.518 ± 1.03400.742 ± 0.98372.642 ± 0.7704
Visit 6: 3 minutes Post-CAC0.679 ± 0.66620.732 ± 0.91270.392 ± 0.57492.542 ± 0.8384
Visit 6: 5 minutes Post-CAC0.920 ± 0.72351.143 ± 0.99870.558 ± 0.63552.592 ± 0.8343
Visit 6: 7 minutes Post-CAC1.000 ± 0.74541.214 ± 0.94210.583 ± 0.67062.483 ± 0.9024
Statistical analysis
  • Bilastine 0.2% vs Bilastine 0% (Vehicle) · ANCOVA · p = 0.0002 · Mean difference (final values): -0.791 · 95% CI -1.203 to -0.378
  • Bilastine 0.4% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -0.851 · 95% CI -1.263 to -0.439
  • Bilastine 0.6% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.545 · 95% CI -1.954 to -1.135
  • Bilastine 0.2% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.208 · 95% CI -1.639 to -0.778
  • Bilastine 0.4% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.245 · 95% CI -1.679 to -0.811
  • Bilastine 0.6% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.846 · 95% CI -2.273 to -1.418
  • Bilastine 0.2% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.696 · 95% CI -2.080 to -1.312
  • Bilastine 0.4% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -1.617 · 95% CI -2.001 to -1.232
  • Bilastine 0.6% vs Bilastine 0% (Vehicle) · ANCOVA · p = <.0001 · Mean difference (final values): -2.009 · 95% CI -2.387 to -1.630

Adverse events

Collected over Safety assessment period (Day 1 through Day 22). Adverts events were assessed at all office visits, throughout a period of 22 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bilastine 0.2%0/30 (0%)0/30 (0%)8/30 (26.7%)
Bilastine 0.4%0/30 (0%)0/30 (0%)3/30 (10%)
Bilastine 0.6%0/31 (0%)0/31 (0%)1/31 (3.2%)
Bilastine 0%0/30 (0%)0/30 (0%)7/30 (23.3%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%
Viral Upper Respiratory Tract InfectionInfections and infestations1/301/300/313/30
Visual Acuity ReducedEye disorders2/300/300/310/30
BlepharitisEye disorders1/300/300/310/30
Corneal DepositsEye disorders0/300/300/311/30
Eye DischargeEye disorders0/300/300/311/30
KeratitisEye disorders0/301/300/310/30
Macular FibrosisEye disorders1/300/300/310/30
HordeolumInfections and infestations1/300/300/310/30
Gastroenteritis ViralInfections and infestations0/300/300/311/30
HeadacheNervous system disorders0/301/300/310/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
<=18 years00000
Between 18 and 65 years28272727109
>=65 years234312
Age, Continuous
Age, Continuous(years)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
Mean50.4 ± 10.747.0 ± 13.9551.8 ± 13.448.3 ± 13.2449.4 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
Female1618151766
Male1412161355
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
Hispanic or Latino374519
Not Hispanic or Latino27232725102
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
American Indian or Alaska Native01001
Asian10102
Native Hawaiian or Other Pacific Islander00000
Black or African American124310
White27272627107
More than one race10001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
United States30303130121
Ocular Itching- Baseline
Ocular Itching- Baseline(units on a scale)Bilastine 0.2%Bilastine 0.4%Bilastine 0.6%Bilastine 0%Total
Visit 4b: Pre- CAC0.058 ± 0.20430.000 ± 0.00000.048 ± 0.19810.025 ± 0.10060.03275 ± 0.12575
Visit 5b: Pre- CAC0.000 ± 0.00000.000 ± 0.00000.033 ± 0.18260.033 ± 0.18260.0165 ± 0.0913
Visit 6: Pre- CAC0.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.00000.000 ± 0.0000
08

Study locations

1 site
  • Ora Clinical Research Center
    Andover, Massachusetts 01810, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Oct 2017, 2 months.

Results were first posted in Nov 2021, 4 years 1 month after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2017
First posted
Jul 27, 2017
StartActual
Jul 20, 2017
Primary completionActual
Oct 11, 2017
CompletionActual
Oct 11, 2017
Results delay requested
Oct 25, 2018
Results first posted
Nov 24, 2021
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03231969
Lead sponsor
Faes Farma, S.A.
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Jul 27, 2017
Start date
Jul 20, 2017
Primary completion
Oct 11, 2017
Completion
Oct 11, 2017
Results posted
Nov 24, 2021
Last update
Mar 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion